Chest
ORIGINAL RESEARCHPULMONARY HYPERTENSIONHigh-Resolution Chest CT Findings Do Not Predict the Presence of Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Section snippets
Study Sample
We retrospectively reviewed the medical records of all patients with IPF who were seen at our institution between July 1999 and June 2006. During the initial visit, all patients prospectively provided written informed consent (approved by the University of California, Los Angeles institutional review board) to use their clinical and demographic information for research purposes. All patients met accepted diagnostic criteria for IPF, and the majority (74%) had histopathologic evidence of usual
Results
The study sample (n = 65) had more advanced pulmonary disease (with lower FVC, diffusing capacity of the lung for carbon monoxide [Dlco], and room air Spo2) than the rest of the cohort (n = 257) but was representative of the cohort with respect to age, gender, and race (Table 1). MPAP in the study sample was similar to the MPAP in the 56 patients with RHC data who were excluded from the study because their RHC was > 1 month distant from their HRCT.
Discussion
PH is common in patients with advanced IPF, and its presence has a significant adverse impact on survival.23 Noninvasive approaches to the diagnosis of PH in patients with IPF are needed. In this study, we found that the CT-determined extent and severity of pulmonary fibrosis and MPAD do not help in identifying PH in advanced IPF patients.
Intuitively, the severity of lung fibrosis should correlate with the prevalence and degree of PH. It seems logical that as IPF progresses and the lungs become
References (42)
- et al.
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis
Chest
(2006) - et al.
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Chest
(2005) - et al.
Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis
Chest
(2007) - et al.
CT scan findings in chronic thromboembolic pulmonary hypertension: predictors of hemodynamic improvement after pulmonary thromboendarterectomy
Chest
(2005) - et al.
Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis
Chest
(2007) - et al.
Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids
Chest
(2000) - et al.
Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia: does Pao2predict survival?
Chest
(2002) Chronic hypoxic pulmonary hypertension: cell biology to pathophysiology
Chest
(1994)- et al.
Magnetic resonance imaging in pulmonary arterial hypertension
Am J Cardiol
(1985) - et al.
The relationship between pulmonary artery pressure and pulmonary artery diameter in pulmonary hypertension
Clin Radiol
(1988)
Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease: Medical College of Wisconsin Lung Transplant Group
Chest
Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement
Am J Respir Crit Care Med
Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases
Respiration
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease
Am J Respir Crit Care Med
CT measurement of main pulmonary artery diameter
Br J Radiol
Relationship between pulmonary artery diameter at computed tomography and pulmonary artery pressures at right-sided heart catheterization: Massachusetts General Hospital Lung Transplantation Program
Acad Radiol
CT-determined pulmonary artery diameters in predicting pulmonary hypertension
Invest Radiol
A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter
J Thorac Imaging
Primary pulmonary hypertension: a national prospective study
Ann Intern Med
Reference spirometric values using techniques and equipment that meet ATS recommendations
Am Rev Respir Dis
Cited by (190)
Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management
2023, The Lancet Respiratory MedicineACR Appropriateness Criteria® Suspected Pulmonary Hypertension: 2022 Update
2022, Journal of the American College of RadiologyPulmonary hypertension in fibrosing idiopathic interstitial pneumonia: Uncertainties, challenges and opportunities
2021, Journal of Heart and Lung TransplantationVasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: A systematic review
2024, BMJ Open Respiratory Research
All work was performed at the David Geffen School of Medicine.
Dr. Zisman received research grants from Actelion Pharmaceuticals and Cotherix Pharmaceuticals to do multicenter studies. Dr. Zisman is funded by the National Institutes of Health IPF Clinical Research Network, which includes participation in a pulmonary hypertension study with sildenafil.
This work was supported, in part, by grants from the National Institutes of Health: 5U10HL080411 and 5P50HL67665 to Dr. Zisman, HL080206 and HL086491 to Dr. Belperio, and AR055075 to Dr. Keane.
The authors have no other conflicts of interest to disclose.